The AIDAC unanimously supported, by a vote of 11-Yes to 0-No, the safety and efficacy of isavuconazonium sulfate capsules and isavuconazonium sulfate for injection, sponsored by Astellas Pharma Global Development, Inc. (Astellas), for the proposed indication of the treatment of invasive aspergillosis.

The AIDAC also supported, by a vote of 8-Yes to 2-No, with one abstention, the safety and efficacy isavuconazonium sulfate capsules and isavuconazonium sulfate for injection, by Astellas, for the proposed indication of the treatment of invasive mucormycosis.